Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Victoza (liraglutide) solution for injection is prescribed to help manage blood sugar and reduce major heart-related risks. Victoza is not safe to use while pregnant and may not be safe to use ...